Evolus (EOLS) Interest & Investment Income (2019 - 2026)
Evolus (EOLS) posted Interest & Investment Income of $285000.0 for Q1 2026, up 8.37% on a QoQ basis from $263000.0 in Q4 2025, and down 59.86% year-over-year from $710000.0 in Q1 2025.
Evolus (EOLS) Interest & Investment Income (2019 - 2026) Analysis & Trends
Evolus' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $285000.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 59.86% year-over-year to $285000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (down 56.42% YoY) and the FY2025 annual result came in at $1.9 million, down 40.82% from the prior year.
- Interest & Investment Income was $285000.0 for Q1 2026 at Evolus, up from $263000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.0 million in Q2 2024 and bottomed at -$203000.0 in Q3 2022.
- A 5-year average of $333764.7 and a median of $291000.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 3000.0% — and 2023, when it plunged 1400.0%.
- Evolus' Interest & Investment Income stood at $31000.0 in 2022, then soared by 838.71% to $291000.0 in 2023, then soared by 171.13% to $789000.0 in 2024, then plunged by 66.67% to $263000.0 in 2025, then grew by 8.37% to $285000.0 in 2026.
- Business Quant data shows EOLS's Interest & Investment Income at $285000.0 in Q1 2026, $263000.0 in Q4 2025, and $479000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Evolus | 403.51 Mn | 353.71 Mn | 48.90 Mn | 285,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 263,000.00 |
| Sep 30, 2025 | 479,000.00 |
| Jun 30, 2025 | 479,000.00 |
| Mar 31, 2025 | 710,000.00 |
| Dec 31, 2024 | 789,000.00 |
| Sep 30, 2024 | 928,000.00 |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 517,000.00 |
| Dec 31, 2023 | 291,000.00 |
| Sep 30, 2023 | 306,000.00 |
| Jun 30, 2023 | -52,000.00 |
| Mar 31, 2023 | -79,000.00 |
| Dec 31, 2022 | 31,000.00 |
| Sep 30, 2022 | -203,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | -103,000.00 |
| Dec 31, 2021 | 1,000.00 |
| Dec 31, 2020 | -3,000.00 |
| Sep 30, 2020 | -16,000.00 |